Lisa Ottenhoff Msw Csw Acsw - Medicare Mental Health Clinic in Battle Creek, MI

Lisa Ottenhoff Msw Csw Acsw is a medicare enrolled mental health clinic (Social Worker - Clinical) in Battle Creek, Michigan. The current practice location for Lisa Ottenhoff Msw Csw Acsw is 391 S Shore Dr Ste 214, Battle Creek, Michigan. For appointments, you can reach them via phone at (269) 964-0153. The mailing address for Lisa Ottenhoff Msw Csw Acsw is 391 S Shore Dr Ste 214, Battle Creek, Michigan and phone number is (269) 964-0153.

Lisa Ottenhoff Msw Csw Acsw is licensed to practice in Michigan (license number 6801065659). The clinic also participates in the medicare program and its NPI number is 1306193602. This medical practice accepts medicare insurance (which means this clinic accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance). However, please confirm if they accept your insurance at (269) 964-0153.

Contact Information

Lisa Ottenhoff Msw Csw Acsw
391 S Shore Dr Ste 214
Battle Creek
MI 49014
(269) 964-0153
(855) 877-5812

Mental Health Clinic Profile

Full NameLisa Ottenhoff Msw Csw Acsw
SpecialitySocial Worker
Location391 S Shore Dr Ste 214, Battle Creek, Michigan
Authorized Official Name and PositionLisa Ottenhoff (OWNER)
Authorized Official Contact2699640153
Accepts Medicare InsuranceYes. This clinic participates in medicare program and accept medicare insurance.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Lisa Ottenhoff Msw Csw Acsw
391 S Shore Dr Ste 214
Battle Creek
MI 49014-5446

Ph: (269) 964-0153
Lisa Ottenhoff Msw Csw Acsw
391 S Shore Dr Ste 214
Battle Creek
MI 49014

Ph: (269) 964-0153

NPI Details:

NPI Number1306193602
Provider Enumeration Date08/07/2012
Last Update Date06/11/2021
Certification Date06/11/2021

Medicare PECOS Information:

Medicare PECOS PAC ID8123305802
Medicare Enrollment IDO20170505001608

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Medical Identifiers

Medical identifiers for Lisa Ottenhoff Msw Csw Acsw such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1306193602NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
1041C0700XSocial Worker - Clinical 6801065659 (Michigan)Primary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Lisa Ottenhoff Msw Csw Acsw acts as a billing entity for following providers:
Provider NameJerry D Gillette
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1831224682
PECOS PAC ID: 7315916434
Enrollment ID: I20040927000434

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameMarilyn C Strobel
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1306954797
PECOS PAC ID: 2769489699
Enrollment ID: I20061107000039

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameLisa Y Ottenhoff
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1083613624
PECOS PAC ID: 9234328584
Enrollment ID: I20110118000994

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameJean Concannon
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1912446139
PECOS PAC ID: 6901181585
Enrollment ID: I20170322000615

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameMarrit Shiery
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1356893960
PECOS PAC ID: 8022394402
Enrollment ID: I20170419002381

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameElizabeth R Chambers
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1780180752
PECOS PAC ID: 0749543189
Enrollment ID: I20180417001147

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameDawn R Lowrance
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1295219558
PECOS PAC ID: 7517219819
Enrollment ID: I20181016000078

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameAmanda J Everett
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1518302173
PECOS PAC ID: 9436371465
Enrollment ID: I20200527001122

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameBlythe B Otter-bugg
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1598258824
PECOS PAC ID: 6002215118
Enrollment ID: I20210521001706

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameGinger Harbin
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1427631613
PECOS PAC ID: 4082013412
Enrollment ID: I20210604000489

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameJamie L Otter
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1356869101
PECOS PAC ID: 9032519111
Enrollment ID: I20210610002334

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameSuzanne C Council
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1124629886
PECOS PAC ID: 8224436530
Enrollment ID: I20211016000045

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameMichele Arlene Bagley
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1689312423
PECOS PAC ID: 9032568845
Enrollment ID: I20231205003041

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameTracy Lee Gogan
Provider TypePractitioner - Clinical Social Worker
Provider IdentifiersNPI Number: 1972830826
PECOS PAC ID: 4587013339
Enrollment ID: I20231206000334

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameEdwina Wallace
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1003382938
PECOS PAC ID: 3577913144
Enrollment ID: I20231221003400

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameLorin Nemrava
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1013045228
PECOS PAC ID: 9931550654
Enrollment ID: I20240108000560

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameTonya Fontes
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1427321736
PECOS PAC ID: 1254782477
Enrollment ID: I20240111002501

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameDennis B Owens
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1508038324
PECOS PAC ID: 6204288541
Enrollment ID: I20240123000459

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

Provider NameLacey Joy Merchant
Provider TypePractitioner - Mental Health Counselor
Provider IdentifiersNPI Number: 1699029082
PECOS PAC ID: 1658717517
Enrollment ID: I20240313003546

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more Medical News

› Verified 4 days ago

News Archive

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

Vanda Pharmaceuticals submits iloperidone NDA

Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

Study finds wild birds as crucial indicators of malaria infection risk

The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.

Read more News

› Verified 4 days ago

Social Worker in Battle Creek, MI

Res-care Premier, Inc.
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 209 Kings Ln, Battle Creek, MI 49014
Phone: 269-753-0491    
Guided Growth Therapy Llc
Mental Health Clinic
Medicare: Medicare Enrolled
Practice Location: 134 Cascade Dr, Battle Creek, MI 49015
Phone: 616-805-9344    
Masters Counseling
Mental Health Clinic
Medicare: Medicare Enrolled
Practice Location: 71 S 20th St, Suite 112, Battle Creek, MI 49015
Phone: 269-965-6058    
Tammy Cairns Lpc Caadc Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 315 Eaton St, Battle Creek, MI 49017
Phone: 269-967-2367    
Peaceful Heart Counseling Llc
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 117 Michigan Ave W, Battle Creek, MI 49017
Phone: 269-967-2760    
Spgb Services
Mental Health Clinic
Medicare: Not Enrolled in Medicare
Practice Location: 32 W Van Buren St, Battle Creek, MI 49017
Phone: 269-964-3830    Fax: 269-964-3833
Christian Counseling Center Of Battle Creek Inc
Mental Health Clinic
Medicare: Medicare Enrolled
Practice Location: 601 S Shore Dr Unit 224, Battle Creek, MI 49014
Phone: 269-979-8119    Fax: 269-979-8124

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.